AstraZeneca’s SERD Etcamah Fails in Phase III First-Line Breast Cancer Trial
AstraZeneca’s SERD Etcamah Fails in Phase III First-Line Breast Cancer Trial GenomeWeb
AstraZeneca’s SERD Etcamah Fails in Phase III First-Line Breast Cancer Trial GenomeWeb
New framework developed for treating liver cancer by UT Southwestern-led research could lead to updated standards The Cancer Letter
Penn Medicine launches first human clinical trial to test precision form of FLASH proton therapy The Cancer Letter
Alcohol-attributable cancer deaths in the U.S. doubled between 1990 and 2023, Sylvester-led study shows The Cancer Letter
Dietary supplement glutamine + standard therapy improved outcomes in advanced pancreatic cancer, Cedars-Sinai investigators find The Cancer Letter
Botensilimab + balstilimab showed no CRC recurrences in resectable colon cancer, phase II NEST trial shows cancerletter.com
Blood cancer patients may have broader stem cell donor options than previously thought, ACCESS trial shows The Cancer Letter
Posts touting mebendazole as cancer treatment go beyond the science AFP Fact Check
Andrew Hsieh named Larry and Virginia Gordon Endowed Chair in Prostate and Bladder Cancer Research at Fred Hutch The Cancer Letter
Posts touting mebendazole as cancer treatment go beyond the science Yahoo
Weizhou Zhang named co-leader of expanded immuno-oncology and microenvironment research program at UF Health Cancer Institute The Cancer Letter
Top 10 Cancer Research Grants Open This Fall Oncodaily
UNC Study Develops Data-Driven Tool to Help Oncologists Identify High-Risk Periods for Metastatic Breast Cancer Patients UNC Health
AstraZeneca breast cancer drug fails late-stage trial goal Investing.com